Metraipolis › archive › dc_ecf0aee7417e

Efficacy and Safety of Vibegron Add-On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α1-Blocker Treatment:… — Europe PMC PMID:41830191

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41830191
DOI
10.1111/luts.70053
License (as archived)
solo-consultazione
Archived
2026-11-05T11:09:03.950Z
SHA-256 of the archived text
12b358aa24b2142d6b22aa3630610b664d1848401652d4ea729c0cf68af0fbe9
Stable URL of this page
https://metraipolis.com/documento/dc_ecf0aee7417e

How to cite

Efficacy and Safety of Vibegron Add-On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α1-Blocker Treatment:… — Europe PMC PMID:41830191 — Europe PMC (en), https://europepmc.org/article/MED/41830191 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ecf0aee7417e (Metraipolis archive dc_ecf0aee7417e, sha256 12b358aa24b2142d6b22aa3630610b664d1848401652d4ea729c0cf68af0fbe9)
BibTeX
@misc{dcecf0aee7417e,
  title = {Efficacy and Safety of Vibegron Add-On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α1-Blocker Treatment:… — Europe PMC PMID:41830191},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41830191},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ecf0aee7417e; sha256 12b358aa24b2142d6b22aa3630610b664d1848401652d4ea729c0cf68af0fbe9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41830191. Agents can read the archived copy with the MCP tool read_document.